Twist Bioscience reported a strong second quarter with revenues of $19.3 million, a 42% increase compared to the same period last year. The company launched new products for SARS-CoV-2 testing and saw an increase in its customer base.
Total revenues were $19.3 million, a 42% increase year-over-year.
Total orders received were $24.6 million, compared to $16.7 million for the same period last year.
Net loss was $31.8 million, or $0.85 per share, compared to $25.9 million, or $0.93 per share, for the same period last year.
Cash, cash equivalents and short term investments totaled $230.1 million as of March 31, 2020.
Due to the unprecedented and uncertain environment, the company withdrew financial guidance for fiscal year 2020, but remains confident in its business and execution.
Analyze how earnings announcements historically affect stock price performance